Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 10/20 | 0.47 |
| ▸ | DDB1 | Q16531 | 9/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6754034 | 0.83 | CRBN (0.47) | CRBNDDB1CA2TDP1PIM1 | |
| SCHEMBL8304222 | 0.82 | CA2 (0.50) | CRBNDDB1CA2TDP1MAPT | |
| SCHEMBL6785305 | 0.79 | CRBN (0.51) | CRBNDDB1CA2PIM1PIM2 | |
| SCHEMBL6788774 | 0.68 | DDB1 (0.54) | CRBNDDB1CA2PIM1PIM2 | |
| SCHEMBL8307240 | 0.67 | CRBN (0.45) | CRBNDDB1CA2ALDH1A1MAPK1 | |
| SCHEMBL19626543 | 0.66 | — | — | |
| SCHEMBL8306896 | 0.66 | CRBN (0.50) | CRBNDDB1CA2TDP1MAPT | |
| SCHEMBL6787966 | 0.64 | F2 (0.39) | CRBNCA2TDP1MAPTKMT2A | |
| SCHEMBL22623703 | 0.64 | DDB1 (1.00) | CRBNDDB1 | |
| SCHEMBL8307313 | 0.64 | GAA (0.37) | CRBNDDB1CA2MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6784184-B2 | FOR THERAPY OF RAS- ONCOGENE-DEPENDENT TUMORS, SUCH AS CANCERS OF PANCREAS, COLON, BLADDER, AND THYROID; USEFUL FOR CONTROLLING METASTASIS, SUPPRESSING ANGIOGENESIS, INDUCING APOPTOSIS, AND RAS-ASSOCIATED PROLIFERATIVE DISEASES | WYETH HOLDINGS CORPORATION | 2004-08-31 | — | — | US | disclosed |
| US-6605628-B1 | Treatment of ras oncogene-dependent tumors; controlling metastasis, suppressing angiogenesis, inducing apoptosis | WYETH HOLDINGS CORPORATION | 2003-08-12 | — | — | US | disclosed |
| US-20030149063-A1 | 5-(arylsulfonyl)-,5-(arylsulfinyl), and 5-(arylsulfanyl)-thiazolidine-2,4-diones useful for inhibition of farnesyl-protein transferase | AMERICAN CYANAMID COMPANY | 2003-08-07 | — | — | US | disclosed |
| US-20030144301-A1 | Method of using 5-(arysulfonyl)-, 5-(arylsulfanyl)-and 5-(arylsulfanyl)thiazolidine-2,4-diones for inhibition of farnesyl-protein transferase | AMERICAN CYANAMID COMPANY (US) | 2003-07-31 | — | — | US | disclosed |
| WO-2003018135-A1 | METHOD OF USING 5-(ARYLSULFONYL)-,5-(ARYLSULFINYL), AND 5-(ARYLSULFANYL)-THIAZOLIDINE-2,4-DIONES FOR INHIBITION OF FARNESYL-PROTEIN TRANSFERASE | WYETH HOLDINGS CORPORATION (US) | 2003-03-06 | — | — | WO | disclosed |
| EP-0749430-B1 | THIAZOLIDINEDIONE DERIVATIVES AS ANTI-HYPERGLYCEMIC AGENTS | AMERICAN HOME PROD (US) | 1999-08-25 | — | — | EP | disclosed |
| US-5605918-A | SUBSTITUTED THIAZOLIDINE-2,4-DIONES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1997-02-25 | — | — | US | disclosed |
| EP-0749430-A1 | THIAZOLIDINEDIONE DERIVATIVES AS ANTI-HYPERGLYCEMIC AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-12-27 | — | — | EP | disclosed |
| US-5574051-A | HYPOGLYCEMIC | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-11-12 | — | — | US | disclosed |
| WO-1995024400-A1 | THIAZOLIDINEDIONE DERIVATIVES AS ANTI-HYPERGLYCEMIC AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1995-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144301-A1 | Method of using 5-(arysulfonyl)-, 5-(arylsulfanyl)-and 5-(arylsulfanyl)thiazolidine-2,4-diones for inhibition of farnesyl-protein transferase | FNTB, FNTA, TST | CRBN 2820/4885DDB1 1439/4885CA2 3820/4885 |
| US-20030149063-A1 | 5-(arylsulfonyl)-,5-(arylsulfinyl), and 5-(arylsulfanyl)-thiazolidine-2,4-diones useful for inhibition of farnesyl-protein transferase | FNTB, FNTA, NAT1 | CRBN 3128/4885DDB1 1073/4885CA2 4148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.